Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease.
Since the late 90s, biopharmaceuticals targeting tumor necrosis factor alpha have revolutionized the treatment of moderately to severely active inflammatory bowel disease. The robust efficacy witnessed in many patients stands in stark contrast with the observation of a proportion of patients who fail to respond or who lose response over time. Therapeutic drug monitoring has been proposed as a means to understand and respond to the variability in clinical response and remission. Various treatment algorithms have been proposed, but optimal use of these measurements in daily practice awaits additional prospective validation trials. This review provides an updated overview on the subject of therapeutic drug monitoring of biopharmaceuticals for the management of inflammatory bowel disease and how we could implement its concepts in a changing landscape.
*Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; †IBD Unit and Endoscopy, Department of Gastroenterology and Hepatology, Hospital Universitario La Paz, Madrid, Spain; and ‡Division of Gastroenterology, Center for Inflammatory Bowel Diseases, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Iris
I
Detrez
Thomas
T
Van Stappen
María D
MD
Martín Arranz
Kostas
K
Papamichael
Ann
A
Gils
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000097:blood / Q000627:therapeutic use; D001688:Biological Products / Q000097:blood* / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods
D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products